medwireNews: METEOR findings show that cabozantinib may prolong time to deterioration (TTD) compared with everolimus, but suggest that the multikinase inhibitor has no significant impact on the quality of life of patients with advanced renal cell carcinoma.
The exploratory analysis follows earlier findings of the trial demonstrating a survival benefit for cabozantinib-treated patients with previously treated disease and bone involvement.
Over 48 weeks of treatment, the two groups had similar responses to the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI) and the five-level EuroQol questionnaire, report David Cella, from Northwestern University Feinberg School of Medicine in Chicago, Illinois, USA, and co-workers.
TTD – defined as death, radiographic disease progression, or at least a 4-point decrease on the FKSI disease-related symptoms survey – took a median of 5.5 months for the cabozantinib arm versus 3.7 months for patients given everolimus, a significant difference that the researchers believe was driven by differences in mortality and disease progression.
“The observed prolongation of TTD in the cabozantinib arm further supports the overall clinical benefit of this agent in addition to improving [progression-free survival], [objective response rate], and [overall survival]—albeit without a QoL advantage,” the team concludes in the Journal of Clinical Oncology.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group
See also: